Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe study's Israel location list was updated to add Tel Litwinsky and remove Qiryat Krinitzi, altering the set of participating sites. Additionally, Melanoma and the MedlinePlus Genetics related topic were added to the page's topics.SummaryDifference0.1%

- Check12 days agoChange DetectedA new recruitment site in Qiryat Krinitzi, Israel, 52621 was added to the study's locations, expanding where participants can enroll. The Melanoma entry, related topics header, MedlinePlus Genetics link, and the Tel Litwinsky, Israel site were removed from the page.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page now includes a 2016 U.S. NIH grant/contract attribution. The release revision has been updated to Revision: v3.6.6, replacing v3.6.5.SummaryDifference0.1%

- Check26 days agoChange DetectedNew related-topic entries were added for Melanoma and MedlinePlus Genetics. These appear under a related topics section to aid context and navigation.SummaryDifference0.1%

- Check33 days agoChange DetectedThree items were removed from the Related topics section: Melanoma, related topics:, and MedlinePlus Genetics. This reduces the set of related topic links shown on the study page.SummaryDifference0.1%

- Check40 days agoChange DetectedMelanoma and related topics (MedlinePlus Genetics) are added and the page revision updated to v3.6.5; the Investigator Inquiry Form is deleted and the prior revision v3.6.4 is superseded.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.